TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22177370

Group type: EXPERIMENTAL
Intervention: Murraya koenigii and Tribulus terrestris-based oral formulation (2 capsules BID for 12 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Tamsulosin (400 μg once daily for 12 weeks)
Number of subjects: 46
Study: 20032914

Group type: EXPERIMENTAL
Intervention: Good Recovery (GR) group
Number of subjects: 13

Group type: COMPARATOR
Intervention: Poor Recovery (PR) group
Number of subjects: 13
Study: 16267070

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation/atrial flutter (AF/AFL)
Number of subjects: 5983
Study: 15618866

Group type: EXPERIMENTAL
Intervention: Nurse telephone intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10886048

Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g t.d.s., amoxycillin 500 mg t.d.s., and clarithromycin 400 mg b.d. (SAC regimen)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg o.m. with the same antimicrobial medications (LAC regimen)
Number of subjects: 150
Study: 9309373

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily
Number of subjects: 315

Group type: COMPARATOR
Intervention: Ofloxacin 400 mg twice daily
Number of subjects: 315
Study: 8326053

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.6 mg/kg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Behavior modification
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combined effects of MPH and behavior modification
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (baseline)
Number of subjects: 31
Study: 2871860

Group type: EXPERIMENTAL
Intervention: Two drug regimen: vincristine 2 mg m‐2 (maximum 2mg) followed by methotrexate 200 mgm‐2, given every three weeks for 54 weeks.
Number of subjects: 194

Group type: COMPARATOR
Intervention: Three drug regimen: vincristine-methotrexate treatment alternating every three weeks with doxorubicin 60 mg m‐2 for 54 weeks.
Number of subjects: 194
Study: 31667584

Group type: EXPERIMENTAL
Intervention: PMTS-guided in-plane epidural access
Number of subjects: 50

Group type: COMPARATOR
Intervention: PMSS-guided in-plane epidural access
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 29343817

Group type: COMPARATOR
Intervention: Normal weight (BMI ≥18.5 to <25)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Every additional unit of BMI over 25 kg/m2
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Secondary endpoints (development of new macroalbuminuria, doubling of creatinine, end stage renal disease, or renal death)
Number of subjects: 10000
Study: 28225522

Group type: EXPERIMENTAL
Intervention: 1 strength training session per week (1W)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 2 strength training sessions per week (2W)
Number of subjects: 35

Group type: COMPARATOR
Intervention: 1 strength training session every second week (0.5W)
Number of subjects: 35

Group type: COMPARATOR
Intervention: 2W vs 1W
Number of subjects: 35

Group type: COMPARATOR
Intervention: 1W and 2W vs 0.5W
Number of subjects: 35
Study: 25074637

Group type: EXPERIMENTAL
Intervention: Dihydrexidine (DAR-0100A) 15 mg/150 ml of normal saline administered intravenously over 30 min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dihydrexidine (DAR-0100A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 23307890

Group type: EXPERIMENTAL
Intervention: Teen mentoring (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adult teacher (control group)
Number of subjects: 0
Study: 21947987

Group type: EXPERIMENTAL
Intervention: Westminster positive protocol
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114

Group type: COMPARATOR
Intervention: Italian negative group
Number of subjects: 114
Study: 18174862

Group type: EXPERIMENTAL
Intervention: Pentavalent human-bovine reassortant rotavirus vaccine
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 16391891

Group type: EXPERIMENTAL
Intervention: Pamidronate (1 mg/kg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Synthetic human calcitonin (1.5 mg)
Number of subjects: 27
Study: 15220685

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily, amoxicillin 1 g, clarithromycin 500 mg (EAC1 group, n = 52)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg (OAC group, n = 52)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg (EAC2 group, n = 52)
Number of subjects: 156
Study: 11055773

Group type: EXPERIMENTAL
Intervention: Homeopathic Betula 30c
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 9120173

Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Tissue-type plasminogen activator (t-PA)
Number of subjects: 358
Study: 8384011

Group type: COMPARATOR
Intervention: Meglumine antimonate (10 mg of antimony/kg intramuscularly, twice a day for 20 days)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Pentamidine (2 mg/kg every other day intramuscularly, for a total of seven injections)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Pentamidine (2 mg/kg every other day for a total of only four injections)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Itraconazole (200 mg orally, twice a day for 28 days)
Number of subjects: 92

Group type: COMPARATOR
Intervention: No treatment (negative control)
Number of subjects: 92
Study: 3774823

Group type: EXPERIMENTAL
Intervention: Active marijuana (1.84% THC)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Active marijuana (2-3 cigarettes during social access period)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo cigarettes
Number of subjects: 9
Study: 29505880

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin (PCV) for 14 days
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Amoxicillin for 14 days
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Doxycycline for 14 days
Number of subjects: 188

Group type: COMPARATOR
Intervention: All treatments (PCV, amoxicillin, doxycycline)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Follow-up for 1 year
Number of subjects: 188
Study: 26455342

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Adenosine >60 minutes after initial PVI
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Adenosine <60 minutes after initial PVI
Number of subjects: 129

Group type: COMPARATOR
Intervention: No adenosine (Control)
Number of subjects: 129
Study: 24530993

Group type: EXPERIMENTAL
Intervention: Hexyl 5‐aminolevulinate hydrochloride (HAL) at a dose of 6.25mg/ml
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hexyl 5‐aminolevulinate hydrochloride (HAL) at a dose of 50mg/ml
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study: 22932169

Group type: EXPERIMENTAL
Intervention: BUD/FORM (160/4.5 µg/inhalation) + as-needed BUD/FORM (640/18 µg/d)
Number of subjects: 222

Group type: COMPARATOR
Intervention: SALM/FP (100/1000 µg/d) + as-needed terbutaline (0.4 mg/inhalation)
Number of subjects: 222
Study: 19736370

Group type: EXPERIMENTAL
Intervention: Interactional group discussions
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study: 17852284

Group type: EXPERIMENTAL
Intervention: Everyday Memory Questionnaire-revised (EMQ-R)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Everyday Memory Questionnaire (EMQ-28)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-clinical)
Number of subjects: 0
Study: 15861510

Group type: EXPERIMENTAL
Intervention: Computer-based teaching program
Number of subjects: 225

Group type: COMPARATOR
Intervention: Traditional teaching program
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Computer-based teaching program (1999 and 2000)
Number of subjects: 225
Study: 12025234

Group type: EXPERIMENTAL
Intervention: Inhibitors of receptor tyrosine kinases (RTK) and Ras
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural and synthetic compounds, monoclonal antibodies, and antisense oligonucleotides as inhibitors of signal transduction
Number of subjects: 0
Study: 11773987

Group type: EXPERIMENTAL
Intervention: verapamil SR/trandolapril 180/2 mg (VT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: enalapril/hydroclorothiazide 20/12.5 mg (EH)
Number of subjects: 93
Study: 9022869

Group type: EXPERIMENTAL
Intervention: Knowledge-and-skills-building workshop for chemical dependency staff on treatment of nicotine dependence
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control sites (no staff training provided)
Number of subjects: 6
Study: 8517568

Group type: EXPERIMENTAL
Intervention: No needle change (venipuncture)
Number of subjects: 940

Group type: COMPARATOR
Intervention: Needle change (venipuncture)
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Freshly inserted IV cannula
Number of subjects: 940

Group type: COMPARATOR
Intervention: Standard method (venipuncture with needle change)
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: IV cannula
Number of subjects: 940
Study: 3782428

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC; 150 mg) for 5 days
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30213463

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Exercise + CPAP
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Exercise and CPAP
Number of subjects: 65

Group type: COMPARATOR
Intervention: Exercise groups
Number of subjects: 65
Study: 27277213

Group type: EXPERIMENTAL
Intervention: ART with TB treatment
Number of subjects: 76

Group type: COMPARATOR
Intervention: TB treatment only
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 76
Study: 24934094

Group type: EXPERIMENTAL
Intervention: Nuvola® aligner
Number of subjects: 2

Group type: COMPARATOR
Intervention: Fantasmino® system
Number of subjects: 2
Study: 22923289

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1,000 IU/day)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1,000 IU/day) in FF subjects (n = 47)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 20012447

Group type: EXPERIMENTAL
Intervention: Lecture delivery
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (rest day)
Number of subjects: 52
Study: 18711188

Group type: EXPERIMENTAL
Intervention: PF-3512676 (0.2 mg/kg subcutaneously on days 8 and 15 of each 3-week cycle)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 111
Study: 16162141

Group type: EXPERIMENTAL
Intervention: Enterococcus faecalis isolates
Number of subjects: 35
Study: 12558709

Group type: EXPERIMENTAL
Intervention: Topical collagen daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: Topical hydrocolloid twice weekly
Number of subjects: 65
Study: 9869576

Group type: EXPERIMENTAL
Intervention: Double combination of zidovudine (ZDV) plus didanosine (ddI)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Triple combination of nevirapine (NVP) plus ZDV plus ddI
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Triple combination of NVP plus ZDV plus ddI
Number of subjects: 175
Study: 8779500

Group type: EXPERIMENTAL
Intervention: Biogel Super‐Sensitive gloves
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Biogel gloves
Number of subjects: 0
Study: 1669595

Group type: EXPERIMENTAL
Intervention: 120 mg terfenadine once daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: 10 mg loratadine once daily
Number of subjects: 40
Study: 30860069

Group type: EXPERIMENTAL
Intervention: Four courses of adjuvant S-1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eight courses of adjuvant S-1
Number of subjects: 0
Study: 28752894

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) and weight loss
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo (PLB) and weight loss
Number of subjects: 165
Study: 26375541

Group type: EXPERIMENTAL
Intervention: Fentanyl ITS (40 mcg/activation)
Number of subjects: 170

Group type: COMPARATOR
Intervention: IV PCA morphine (1 mg/dose)
Number of subjects: 170
Study: 23418751

Group type: EXPERIMENTAL
Intervention: Skinfold thickness measurement (SFTM)
Number of subjects: 49
Study: 21537587

Group type: EXPERIMENTAL
Intervention: Marginal Sealing (n=48)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Refurbishment (n=73)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Repair (n=27)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Replacement (n=42)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Untreated (n=81)
Number of subjects: 66
Study: 19138701

Group type: EXPERIMENTAL
Intervention: Near-work induced transient myopia (NITM) in progressing myopes (PMs)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Steady-state accommodative stimulus response curve (ASRC)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Near-work induced transient myopia (NITM)
Number of subjects: 3
Study: 18074759

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg
Number of subjects: 36
Study: 15177522

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/d for 6 months
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Probucol 500 mg/d for 6 months
Number of subjects: 52
Study: 11589258

Group type: EXPERIMENTAL
Intervention: Tramadol/APAP (37.5 mg/325 mg)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Codeine/APAP (30 mg/300 mg)
Number of subjects: 462
Study: 11477815

Group type: EXPERIMENTAL
Intervention: Xianzhen Tablet (XZT) treated group, 30 patients, 8 weeks treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 60
Study: 8608658

Group type: EXPERIMENTAL
Intervention: PAN DX membrane dialyzer
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Polysulfone membrane dialyzer
Number of subjects: 12

Group type: COMPARATOR
Intervention: Concurrent ACE inhibitor
Number of subjects: 12

Group type: COMPARATOR
Intervention: No ACE inhibitor
Number of subjects: 12
Study: 2756523

Group type: EXPERIMENTAL
Intervention: 300 mg of propafenone on days 1 and 4, 1200 mg/day on days 2 and 3
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 600 mg of propafenone on days 1 and 4, 1200 mg/day on days 2 and 3
Number of subjects: 10

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 10
Study: 68382

Group type: EXPERIMENTAL
Intervention: Direct-current bone-growth stimulator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31102525

Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability (VVV) in blood pressure (BP) measured as standard deviation (SD) of systolic blood pressure (SBP)
Number of subjects: 10051

Group type: EXPERIMENTAL
Intervention: Coefficient of variation (CV) of SBP
Number of subjects: 10051
Study: 31131517

Group type: COMPARATOR
Intervention: Aerobic Training (AT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Resistance Training (RT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Combined Training (CT)
Number of subjects: 48
Study: 28240587

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg weekly
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Extreme scores (enthesitis and/or BASDAI)
Number of subjects: 213
Study: 25979190

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied during the bone consolidation period following mandibular distraction osteogenesis.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mandibular distraction osteogenesis without LLLT (Control group).
Number of subjects: 10
Study: 24287217

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) cycling four times a week for two weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard rehabilitation for two weeks
Number of subjects: 14
Study: 21527222

Group type: EXPERIMENTAL
Intervention: Z-plasty during two-stage hypospadias repair (Group I)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Secondary Z-plasty (Group II)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Midline vertical closure (Group III - Control)
Number of subjects: 43
Study: 18272020

Group type: EXPERIMENTAL
Intervention: 10 mg morphine sulphate (p.o.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16951513

Group type: EXPERIMENTAL
Intervention: Hospice care
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional nursing
Number of subjects: 76
Study: 15055563

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aqueous nasal spray (TAA AQ), 220 microg everyday for 21 days
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FP AQ), 200 microg everyday for 21 days
Number of subjects: 39
Study: 11093991

Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 81

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 81
Study: 9460590

Group type: EXPERIMENTAL
Intervention: Atenolol therapy for 6 months
Number of subjects: 0
Study: 8463375

Group type: EXPERIMENTAL
Intervention: Frightening story
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Frightening-happy end story
Number of subjects: 132

Group type: COMPARATOR
Intervention: Pause story
Number of subjects: 132

Group type: COMPARATOR
Intervention: Neutral story
Number of subjects: 132
Study: 3456621

Group type: EXPERIMENTAL
Intervention: 20 mg PGE2/day/patient (5 mg every 4 hours, 4 times a day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 20 mg lactose/day/patient (placebo)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sodium bicarbonate
Number of subjects: 10
Study: 31914436

Group type: EXPERIMENTAL
Intervention: Nivolumab with or without ipilimumab
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 2
Study: 29448361

Group type: EXPERIMENTAL
Intervention: Real networks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Degree-preserving randomizations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Certain real networks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uncorrelated random networks
Number of subjects: 0
Study: 26859101

Group type: EXPERIMENTAL
Intervention: Anastrozole plus fulvestrant
Number of subjects: 694

Group type: COMPARATOR
Intervention: Anastrozole alone
Number of subjects: 694
Study: 24763475

Group type: EXPERIMENTAL
Intervention: FLEX
Number of subjects: 35

Group type: COMPARATOR
Intervention: SMILE
Number of subjects: 35
Study: 23442835

Group type: COMPARATOR
Intervention: Esomeprazole 20 mg, Esomeprazole 40 mg
Number of subjects: 11831

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg, Lansoprazole 30 mg
Number of subjects: 11831

Group type: COMPARATOR
Intervention: Esomeprazole vs. Placebo
Number of subjects: 11831

Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 11831
Study: 19881393

Group type: EXPERIMENTAL
Intervention: Azithromycin 30 mg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Azithromycin 20 mg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Erythromycin 50 mg/kg for 5 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: No antibiotic (control)
Number of subjects: 120
Study: 18948636

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1.8 g daily for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle-treated groups
Number of subjects: 0
Study: 17304477

Group type: EXPERIMENTAL
Intervention: Teletherapy combined with radioisotope therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Teletherapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Radioisotope therapy
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combined treatment (radiotherapy and radioisotopes)
Number of subjects: 84
Study: 12711881

Group type: EXPERIMENTAL
Intervention: Transvenous low-energy intracardiac biphasic direct-current (DC) cardioversion (ICV) using a single-lead balloon-tipped catheter
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional high-energy transthoracic monophasic DC cardioversion (TCV)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Follow-up after ICV
Number of subjects: 54
Study: 11908358

Group type: EXPERIMENTAL
Intervention: Colgate Sensitive Maximum Strength Toothpaste (5.0% potassium nitrate, 0.454% stannous fluoride)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sensodyne Fresh Mint Toothpaste (5.0% potassium nitrate, 0.243% sodium fluoride)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Colgate Winterfresh Gel (0.243% sodium fluoride)
Number of subjects: 120
Study: 8731383

Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor I (100 micrograms/kg)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Cu/Zn‐SOD activity
Number of subjects: 73

Group type: COMPARATOR
Intervention: Vitamin E, vitamin C, and beta‐carotene
Number of subjects: 73

Group type: COMPARATOR
Intervention: Catalase activity
Number of subjects: 73
Study: 1578940

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplant (Allo-BMT)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplant (Auto-BMT)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Not randomized patients (intention to treat analysis)
Number of subjects: 155
Study: 3862020

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti‐inflammatory agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of corticosteroids and nonsteroidal anti‐inflammatory agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28651477

Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Active psycho-educative control intervention
Number of subjects: 70
Study: 28366780

Group type: EXPERIMENTAL
Intervention: ED‐focused intervention to improve the quality of care on discharge to home
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ED‐focused intervention together with a home‐based community health worker (CHW)‐led intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 0